Merck & Co (MRK) Announced Positive Results From Phase 3 HYPERION Trial of WINREVAIR

Merck & Co., Inc. (NYSE:MRK) is one of the Top Blue Chip Stocks to Buy At 52-Week Lows. On September 30, Merck & Co., Inc. (NYSE:MRK) announced  positive results from its Phase 3 HYPERION trial of WINREVAIR in adults recently diagnosed with pulmonary arterial hypertension.

The trial included patients classified as functional class 2 or 3 and at intermediate or high risk of disease progression. Management noted that the drug reduced the risk of clinical worsening events by 76% compared to placebo. Moreover, the benefit of WINREVAIR was seen early, within six weeks of starting treatment, and sustained throughout the trial. The results were consistent across patient subgroups, including those with idiopathic PAH and connective tissue disease. Lastly, the safety profile remained consistent with previous trials.3

Merck & Co., Inc. (NYSE:MRK) is a global healthcare company focused on developing and delivering prescription medicines, vaccines, and animal health products.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.